レビー小体型認知症治療の世界市場レポート 2025年

レビー小体型認知症治療市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は7.0％で、61億7,000万米ドルに成長します。予測期間の成長は、神経学の進歩、重点的な調査イニシアティブ、精密医療とバイオマーカー、共同ヘルスケアモデル、遠隔医療の拡大に起因しています。予測期間の主な動向には、家族や介護者の支援、統合ケアモデル、個別化治療アプローチ、非薬物療法的介入、デジタルヘルスソリューションなどが含まれます。

レビー小体型認知症治療市場は、脳関連疾患の有病率の増加により成長が見込まれています。脳障害には、脳機能に影響を及ぼす疾患が含まれ、脳損傷の程度によって軽度から重度の障害まです。リーワイ小体型認知症の治療は、注意力や認知力を向上させるために脳内化学物質を強化することで、幻覚、錯乱、眠気などの症状に対処することを目的としています。2022年1月に米国心臓協会（American Heart Association Inc.）が発表した報告書によると、2060年までに米国で脳障害が930万人に増加すると予測されています。現在、脳障害の有病率は世界的に上昇傾向にあり、世界の6人に1人が罹患しており、2021年には10億人が脳障害に罹患すると推定されています。このような脳関連疾患の急増は、レビー小体型認知症治療市場の重要な促進要因となっています。

レビー小体型認知症治療市場の成長は、高齢化人口の増加によって促進されると予想されます。高齢化は、社会における高齢者の割合の増加を特徴とする人口動態の変化を意味します。レビー小体型認知症治療は、この進行性神経変性障害に罹患した高齢者の症状を管理し、認知機能を高め、生活の質を向上させる上で重要な役割を果たしています。2022年10月の世界保健機関（WHO）の予測によると、2030年までに世界の6人に1人が60歳以上になるといいます。60歳以上の人口の割合は、2020年の10億人からこの間に14億人に増加すると予想されています。さらに、60歳以上の世界人口は2050年までに倍増し、21億人に達すると予想されています。その結果、高齢化人口の増加がレビー小体型認知症治療市場を牽引する重要な要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界レビー小体型認知症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、制約）
• 最終用途産業の分析
• 世界のレビー小体型認知症治療市場：成長率分析
• 世界のレビー小体型認知症治療市場の実績：規模と成長, 2019-2024
• 世界のレビー小体型認知症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界レビー小体型認知症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のレビー小体型認知症治療市場薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗うつ薬
• 抗精神病薬
• ベンゾジアゼピン
• カルビドパ-レボドパ
• コリンエステラーゼ阻害剤
• モダフィニル
• 世界のレビー小体型認知症治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界のレビー小体型認知症治療市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アルツハイマー病
• 痴呆
• パーキンソン病
• 世界のレビー小体型認知症治療市場抗うつ薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 選択的セロトニン再取り込み阻害薬（SSRI）
• 三環系抗うつ薬
• 世界のレビー小体型認知症治療市場抗精神病薬の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非定型抗精神病薬
• 典型的な抗精神病薬
• 世界のレビー小体型認知症治療市場ベンゾジアゼピンの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 短時間作用型ベンゾジアゼピン
• 長時間作用型ベンゾジアゼピン
• 世界のレビー小体型認知症治療市場、カルビドパ-レボドパのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 即効性製剤
• 徐放性製剤
• 世界のレビー小体型認知症治療市場、コリンエステラーゼ阻害剤のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ドネペジル
• リバスチグミン
• ガランタミン
• 世界のレビー小体型認知症治療市場モダフィニルの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標準処方
• 徐放性製剤

第7章 地域別・国別分析

• 世界のレビー小体型認知症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のレビー小体型認知症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• レビー小体型認知症治療市場：競合情勢
• レビー小体型認知症治療市場：企業プロファイル
  • Mallinckrodt Pharmaceuticals Co. Overview, Products and Services, Strategy and Financial Analysis
  • BioArctic AB Overview, Products and Services, Strategy and Financial Analysis
  • Sumitomo Pharma Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Jazz Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Allergan plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis International AG
• Pfizer Inc.
• Bayer AG
• Boehringer Ingelheim International GmbH.
• Merck & Co. Inc.
• Biogen Inc.
• Biohaven Pharmaceutical Holding Company Ltd.
• Bristol Myers Squibb Company
• Calliditas Therapeutics AB
• Chiesi USA Inc.
• GlaxoSmithKline plc
• Eisai Co. Ltd.
• Bausch Health Companies Inc.
• Hisamitsu Pharmaceutical Co. Inc.
• Lundbeck Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• レビー小体型認知症治療市場2029：新たな機会を提供する国
• レビー小体型認知症治療市場2029：新たな機会を提供するセグメント
• レビー小体型認知症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Lewy body dementia treatment encompasses both medications and nonmedical therapies aimed at managing symptoms and improving the overall well-being of individuals affected by the condition. Nonmedical therapies include physical, occupational, and speech therapies, while medications are used to alleviate symptoms such as hallucinations, confusion, drowsiness, movement problems, and disturbed sleep.

The main drug types in the Lewy body dementia treatment market include antidepressants, antipsychotic drugs, benzodiazepines, carbidopa-levodopa, cholinesterase inhibitors, and modafinil. Antidepressants are medications prescribed to treat depression and various related conditions, such as anxiety disorders, obsessive-compulsive disorder (OCD), chronic pain, eating disorders, and post-traumatic stress disorder (PTSD). They work by increasing the levels of certain chemicals in the brain to improve mood. Distribution channels for these treatments include hospitals pharmacies, retail pharmacies, online pharmacies, and others. These treatments are commonly used for conditions such as Alzheimer's disease, dementia, and Parkinson's disease.

The lewy body dementia treatment market research report is one of a series of new reports from The Business Research Company that provides lewy body dementia treatment market statistics, including lewy body dementia treatment industry global market size, regional shares, competitors with a lewy body dementia treatment market share, detailed lewy body dementia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the lewy body dementia treatment industry. This lewy body dementia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lewy body dementia treatment market size has grown strongly in recent years. It will grow from $4.43 billion in 2024 to $4.71 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to supportive care and family education, regulatory approvals and guideline, multidisciplinary care approaches, psychosocial and behavioral interventions, multidisciplinary care approaches.

The lewy body dementia treatment market size is expected to see strong growth in the next few years. It will grow to $6.17 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to advancements in neurology, focused research initiatives, precision medicine and biomarkers, collaborative healthcare models, telemedicine expansion. Major trends in the forecast period include family and caregiver support, integrated care models, personalized treatment approaches, non-pharmacological interventions, digital health solutions.

The lewy body dementia treatment market is anticipated to witness growth due to the increasing prevalence of brain-related disorders. Brain disorders encompass conditions that impact brain function, ranging from mild to severe impairment depending on the extent of brain damage. Treatments for lewy body dementia aim to address symptoms such as hallucinations, confusion, and drowsiness by enhancing brain chemicals to improve alertness and cognition. A report shared by the American Heart Association Inc. in January 2022 indicated a projected increase in brain disorders to 9.3 million in the US by 2060. Currently, the prevalence of brain disorders is on the rise globally, affecting one in every six people worldwide, with an estimated 1 billion individuals suffering from brain disorders by 2021. This surge in brain-related disorders is a significant driver for the lewy body dementia treatment market.

The growth of the Lewy body dementia treatment market is expected to be propelled by the rising aging population. An aging population signifies a demographic shift characterized by an increasing proportion of elderly individuals within society. Lewy body dementia treatments play a crucial role in managing symptoms, enhancing cognitive function, and improving the quality of life for the aging population affected by this progressive neurodegenerative disorder. According to the World Health Organization's projections in October 2022, by 2030, one out of every six individuals globally will be 60 years old or older. The proportion of the population aged 60 and over is expected to rise from 1 billion in 2020 to 1.4 billion during this period. Moreover, the global population of individuals aged 60 and older is anticipated to double by 2050, reaching 2.1 billion. Consequently, the rising aging population is a significant factor driving the Lewy body dementia treatment market.

Innovation emerges as a key trend in the lewy body dementia treatment market, with major companies focusing on developing innovative solutions to strengthen their market positions. Biogen Inc., a multinational biotechnology company, introduced lecanemab in January 2023. This humanized monoclonal antibody is designed to treat Alzheimer's disease, which is a component of Lewy body dementia. Lecanemab stands out by reducing brain amyloid levels, addressing amyloid plaques believed to contribute to cognitive impairment and dementia in Alzheimer's disease.

Major companies in the lewy body dementia treatment market are also concentrating on providing revolutionary transdermal systems that leverage innovative technology, such as CORPLEX technology for Alzheimer's dementia treatment. Corium, a biopharmaceutical leader in CNS therapies, launched ADLARITY in September 2022. This once-weekly transdermal system delivers donepezil for Alzheimer's patients, addressing the disease component in Lewy body dementia. Utilizing CORPLEX technology, it ensures sustained drug release for enhanced efficacy and reduced gastrointestinal side effects.

In October 2022, Pfizer Inc., a multinational pharmaceutical and biotechnology corporation, acquired Biohaven Pharmaceuticals Inc. for $11.6 billion. This strategic acquisition aims to enhance Pfizer's potential to offer new treatment options globally. Biohaven Pharmaceuticals Inc. is a pharmaceutical company focused on developing drugs for the treatment of Parkinson's disease, which is related to Lewy body dementia.

Major companies operating in the lewy body dementia treatment market include Mallinckrodt Pharmaceuticals Co., BioArctic AB, Sumitomo Pharma Co. Ltd., Jazz Pharmaceuticals Inc., Allergan plc, Novartis International AG, Pfizer Inc., Bayer AG, Boehringer Ingelheim International GmbH., Merck & Co. Inc., Biogen Inc., Biohaven Pharmaceutical Holding Company Ltd., Bristol Myers Squibb Company, Calliditas Therapeutics AB, Chiesi USA Inc., GlaxoSmithKline plc, Eisai Co. Ltd., Bausch Health Companies Inc., Hisamitsu Pharmaceutical Co. Inc., Lundbeck Inc.

North America was the largest region in the Lewy body dementia treatment market in 2024. The regions covered in the lewy body dementia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the lewy body dementia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lewy body dementia treatment market consists of revenues earned by entities by providing speech and language therapy, physiotherapy, and psychological therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The lewy body dementia treatment market also includes sales of rivastigmine, donepezil, and galantamine products, which are used in providing lewy body dementia treatment services. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lewy Body Dementia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lewy body dementia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lewy body dementia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lewy body dementia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Antidepressants; Antipsychotic Drugs; Benzodiazepine; Carbidopa-Levodopa; Cholinesterase inhibitors; Modafinil
• 2) By Distribution Channel: Hospitals Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• 3) By Application: Alzheimer's disease; Dementia; Parkinson's disease
• Subsegments:
• 1) By Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs); Tricyclic Antidepressants
• 2) By Antipsychotic Drugs; Atypical Antipsychotics: Typical Antipsychotics
• 3) By Benzodiazepines: Short-acting Benzodiazepines; Long-acting Benzodiazepines
• 4) By Carbidopa-Levodopa: Immediate-Release Formulations; Extended-Release Formulations
• 5) By Cholinesterase Inhibitors: Donepezil; Rivastigmine; Galantamine
• 6) By Modafinil: Standard Formulations; Extended-Release Formulations
• Companies Mentioned: Mallinckrodt Pharmaceuticals Co.; BioArctic AB; Sumitomo Pharma Co. Ltd.; Jazz Pharmaceuticals Inc.; Allergan plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Lewy Body Dementia Treatment Market Characteristics

3. Lewy Body Dementia Treatment Market Trends And Strategies

4. Lewy Body Dementia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Lewy Body Dementia Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Lewy Body Dementia Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Lewy Body Dementia Treatment Market Growth Rate Analysis
• 5.4. Global Lewy Body Dementia Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Lewy Body Dementia Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Lewy Body Dementia Treatment Total Addressable Market (TAM)

6. Lewy Body Dementia Treatment Market Segmentation

• 6.1. Global Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antidepressants
• Antipsychotic Drugs
• Benzodiazepine
• Carbidopa-Levodopa
• Cholinesterase inhibitors
• Modafinil
• 6.2. Global Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.3. Global Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alzheimer's disease
• Dementia
• Parkinson's disease
• 6.4. Global Lewy Body Dementia Treatment Market, Sub-Segmentation Of Antidepressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Tricyclic Antidepressants
• 6.5. Global Lewy Body Dementia Treatment Market, Sub-Segmentation Of Antipsychotic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atypical Antipsychotics
• Typical Antipsychotics
• 6.6. Global Lewy Body Dementia Treatment Market, Sub-Segmentation Of Benzodiazepines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Short-acting Benzodiazepines
• Long-acting Benzodiazepines
• 6.7. Global Lewy Body Dementia Treatment Market, Sub-Segmentation Of Carbidopa-Levodopa, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immediate-Release Formulations
• Extended-Release Formulations
• 6.8. Global Lewy Body Dementia Treatment Market, Sub-Segmentation Of Cholinesterase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Donepezil
• Rivastigmine
• Galantamine
• 6.9. Global Lewy Body Dementia Treatment Market, Sub-Segmentation Of Modafinil, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard Formulations
• Extended-Release Formulations

7. Lewy Body Dementia Treatment Market Regional And Country Analysis

• 7.1. Global Lewy Body Dementia Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Lewy Body Dementia Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lewy Body Dementia Treatment Market

• 8.1. Asia-Pacific Lewy Body Dementia Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lewy Body Dementia Treatment Market

• 9.1. China Lewy Body Dementia Treatment Market Overview
• 9.2. China Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lewy Body Dementia Treatment Market

• 10.1. India Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lewy Body Dementia Treatment Market

• 11.1. Japan Lewy Body Dementia Treatment Market Overview
• 11.2. Japan Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lewy Body Dementia Treatment Market

• 12.1. Australia Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lewy Body Dementia Treatment Market

• 13.1. Indonesia Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lewy Body Dementia Treatment Market

• 14.1. South Korea Lewy Body Dementia Treatment Market Overview
• 14.2. South Korea Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lewy Body Dementia Treatment Market

• 15.1. Western Europe Lewy Body Dementia Treatment Market Overview
• 15.2. Western Europe Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lewy Body Dementia Treatment Market

• 16.1. UK Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lewy Body Dementia Treatment Market

• 17.1. Germany Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lewy Body Dementia Treatment Market

• 18.1. France Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lewy Body Dementia Treatment Market

• 19.1. Italy Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lewy Body Dementia Treatment Market

• 20.1. Spain Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lewy Body Dementia Treatment Market

• 21.1. Eastern Europe Lewy Body Dementia Treatment Market Overview
• 21.2. Eastern Europe Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lewy Body Dementia Treatment Market

• 22.1. Russia Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lewy Body Dementia Treatment Market

• 23.1. North America Lewy Body Dementia Treatment Market Overview
• 23.2. North America Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lewy Body Dementia Treatment Market

• 24.1. USA Lewy Body Dementia Treatment Market Overview
• 24.2. USA Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lewy Body Dementia Treatment Market

• 25.1. Canada Lewy Body Dementia Treatment Market Overview
• 25.2. Canada Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lewy Body Dementia Treatment Market

• 26.1. South America Lewy Body Dementia Treatment Market Overview
• 26.2. South America Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lewy Body Dementia Treatment Market

• 27.1. Brazil Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lewy Body Dementia Treatment Market

• 28.1. Middle East Lewy Body Dementia Treatment Market Overview
• 28.2. Middle East Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lewy Body Dementia Treatment Market

• 29.1. Africa Lewy Body Dementia Treatment Market Overview
• 29.2. Africa Lewy Body Dementia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Lewy Body Dementia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Lewy Body Dementia Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lewy Body Dementia Treatment Market Competitive Landscape And Company Profiles

• 30.1. Lewy Body Dementia Treatment Market Competitive Landscape
• 30.2. Lewy Body Dementia Treatment Market Company Profiles
  • 30.2.1. Mallinckrodt Pharmaceuticals Co. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. BioArctic AB Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sumitomo Pharma Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Jazz Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Allergan plc Overview, Products and Services, Strategy and Financial Analysis

31. Lewy Body Dementia Treatment Market Other Major And Innovative Companies

• 31.1. Novartis International AG
• 31.2. Pfizer Inc.
• 31.3. Bayer AG
• 31.4. Boehringer Ingelheim International GmbH.
• 31.5. Merck & Co. Inc.
• 31.6. Biogen Inc.
• 31.7. Biohaven Pharmaceutical Holding Company Ltd.
• 31.8. Bristol Myers Squibb Company
• 31.9. Calliditas Therapeutics AB
• 31.10. Chiesi USA Inc.
• 31.11. GlaxoSmithKline plc
• 31.12. Eisai Co. Ltd.
• 31.13. Bausch Health Companies Inc.
• 31.14. Hisamitsu Pharmaceutical Co. Inc.
• 31.15. Lundbeck Inc.

32. Global Lewy Body Dementia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lewy Body Dementia Treatment Market

34. Recent Developments In The Lewy Body Dementia Treatment Market

35. Lewy Body Dementia Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Lewy Body Dementia Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Lewy Body Dementia Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Lewy Body Dementia Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer